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A B S T R A C T
MicroRNAs (MiRNAs) have emerged as pivotal modulators of mammalian cardio-
vascular development and disease over the past few years. They represent a biological 
mechanism for regulating gene expression and consequently a broad range of physi-
ological and pathological molecular processes. Importantly, multiple miRNAs have 
been implicated in heart disease onset and progression, whereas in the case of cardiac 
hypertrophy and heart failure, recent data are changing our perception of disease 
pathogenesis and therapeutics. This review presents the concept of miRNAs, mecha-
nisms of generation, and representative examples of associations with cardiovascular 
disease pathogenesis and therapeutic potential.
I N T R O D U C T I O N
The 21st century is considered by many the era of Genomic Medicine. Indeed fas-
cinating advances have been achieved both in terms of high-throughput technologies 
and biological insight, leading to a deeper understanding of human disease, improved 
diagnostic and prognostic tools, and better therapeutic approaches. In Cardiology, 
extensive work over decades led to the identification of genetic and environmental 
factors contributing to disease pathogenesis. However, genetics alone does not suf-
fice to explain the full pathological spectrum and variable prognosis of these complex 
multifactorial heart diseases. Furthermore, available therapies are far from ideal. 
The latest advances in genomics are now opening the way to a new era for Molecular 
Cardiology, with novel concepts and molecules meriting in depth exploration. One of 
the most rapidly evolving cases is this of microRNAs (miRNAs).
Micro-RNAs (miRNAs) have emerged as pivotal modulators of mammalian 
cardiovascular development and disease over the past few years. They represent an-
other biological mechanism for regulating gene expression and consequently a broad 
range of physiological and pathological molecular processes. MiRNAs are a group of 
small (18-25 nucleotide-long), single stranded, evolutionary conserved, non-coding 
regulatory RNA molecules. They are transcribed from DNA (intergenic, intronic or 
polycistronic) but are not translated into proteins. Instead, they bind messenger RNA 
(mRNA) molecules and interfere with their stability and consequantly their translation 
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AbbreviAtions
cTnI = cardiac troponin I 
DNA = deoxyribonucleic acid
DYRK = dual-specificity tyrosine 
phosphorylation-regulated kinase 
GATA = (transcription factor binding 
to the consensus DNA sequence) 
guanine/adenine/ thymine/adenine 
HSP = heat shock protein
LNA = locked-nucleic acid 
MEF2A = myocyte-specific enhancer 
factor 2A 
miRNA = micro RNA
mRNA = messenger RNA
MuRF1 = muscle ring finger1 
NFATc3 = nuclear factor of activated T 
cells 3 
PPARγ = peroxisome proliferator-
activated receptor γ 
PTGS = post transcriptional gene 
silencing 
RISC = RNA-induced silencing 
complex, also known as a microRNA 
ribonucleoprotein complex (miRNP)
RNA = ribonucleic acid
Thrap1 = thyroid hormone receptor-
associated protein 1 
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to proteins. The primary transcripts of miRNAs, pri- miRNAs, 
are hairpin-shaped molecules bearing a 5’cap and a poly (A) 
adenosine tail on the 3’edge.1,2 After a first processing step 
inside the nucleus by the Microprocessor complex (Dorsha 
nuclease and Pasha protein) 70 nucleotide-long pre-miRNAs 
are generated. In turn, they are transported to the cytoplasm 
by exportin 5, and cleaved by the Dicer protein to form mature 
double stranded miRNA molecules (Fig. 1).3-5 These double-
stranded molecules are cut into two single-stranded miRNAs, 
with the “active” one being chosen by the Argonaut protein 
and embodied in a protein complex to form the active miRNP 
complex (miRNA-containing ribonucleoprotein particle) and 
the remaining one being decomposed.6-9 
The mature miRNA can direct miRNP complexes to the 
FIgURE 1. Schematic representation of microRNAs’ formation and course of action. MicroRNAs (miRNAs) are transcribed from 
intergenic, intronic or polycistronic DNA, in the first instance as hairpin-shaped molecules (primary transcript or pri- miRNAs), 
which bear a 5’cap and a poly (A) adenosine tail on the 3’edge. Inside the nucleus, these primary transcripts are modified by the 
Microprocessor complex (Dorsha nuclease and Pasha protein) to form 70 nucleotide-long pre-miRNAs. Exportin 5 facilitate pre-
miRNAs translocation to the cytoplasm, where they are cleaved by the Dicer protein to form mature double stranded 18-25 nucleo-
tide-long miRNA molecules. After being cut into two single stranded miRNAs, the “active” one is selected by the Argonaut protein 
and embodied in a protein complex to form the active miRNP. The remaining single stranded miRNA is decomposed. The miRNP 
complexes are directed to the appropriate mRNA targets and bind multiple, partially complementary sites in their 3’-UTR regions. 
In the case of perfect base-pairing the target mRNA is destroyed, whereas partial binding multiple miRNAs to an mRNA results in 
reduced levels of the corresponding protein with minimum effect on the mRNA levels. 3’UTR = three prime untranslated regions; 
DNA = deoxyribonucleic acid; ds = double-stranded; mRNA = messenger RNA; RNA = ribonucleic acid; RISC = RNA-induced 
silencing complex, also known as a microRNA ribonucleoprotein complex (miRNP); ss = single-stranded. 
appropriate mRNA targets using their base-pair complemen-
tarity, and thus regulate mRNA expression levels. As reported 
for most animal miRNAs, they can bind multiple, partially 
complementary sites in the 3’-UTR regions of target mRNAs, 
and in the case of perfect base-pairing the target mRNA is 
destroyed.10 Alternatively, multiple miRNAs may bind partially 
to an mRNA, resulting in reduced levels of the correspond-
ing protein with minimum effect on the mRNA levels.11 The 
overall outcome is post transcriptional gene silencing (PTGS).
MicroRNAs are implicated in numerous physiological 
functions, including cell- and tissue- specific differentiation 
and development. Closing up to the cardiovascular system, a 
role for miRNAs has been proposed in cardiac development 
and function, as well as in heart disease. Multiple miRNAs 
MICRO-RNAs IN HEART DISEASE
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M I C R O R N A s  R E L A T E D  T O 
C A R D I O V A S C U L A R  P A T H O g E N E S I S
A representative study from this field involved global 
miRNA expression profiling in the left ventricles of heart 
failure patients. It showed significant alterations in many 
miRNAs, indicating that they hold a key role in disease patho-
genesis and progression. The reported changes varied based on 
the primary disease (e.g. dilated or ischemic cardiomyopathy or 
aortic stenosis) and they were sufficiently distinct to allow accu-
rate patient classification.12 Of note, 87% of the over-expressed 
miRNAs along with 84% of the under-expressed miRNAs in 
those tissues were similar to the miRNA expression profiles of 
fetal heart tissue, thus implicating the specific miRNAs in the 
activation of the “fetal gene expression program”, a hallmark 
of the hypertrophic and failing myocardium.13 
P R O - H y P E R T R O P H I C  M i R N A s
Other studies in hypertrophic hearts from humans and 
mouse models identified significantly elevated miR-195 
levels. In vitro and in vivo analysis of miR-195 proved that its 
overexpression is sufficient for the development of cardiac 
hypertrophy over the course of a few weeks, and development 
of dilated cardiomyopathy and heart failure in the long-term.14 
MiR-23a, miR-23b, miR-24 and miR-214 were also found 
overexpressed in cardiac hypertrophy. In order to assess their 
contribution to disease pathogenesis, they were overexpressed 
in cardiomyocytes in vitro, and as hypothesized, they led to 
hypertrophy. In contrast to miR-195, miR-214 overexpression 
TABLE 1. Examples of MicroRNA Involvement in Cardiac 
Pathophysiology.
MicroRNAs Pathological effect/outcome 
miR-195 in vivo hypertrophy, dilated cardiomyopathy 
miR-23a in vivo hypertrophy 
miR-23b in vivo hypertrophy 
miR-24 in vivo hypertrophy 
miR-214 in vitro hypertrophy 
miR-21 
miR-129 
miR-212 
in vivo hypertrophy
miR-199a in vivo hypertrophy 
miR-199b in vivo hypertrophy, heart failure 
miR-27b in vivo hypertrophy, heart failure 
miR-208a 
miR-499 
in vivo hypertrophy, arrhythmias 
miR-1 
miR-133 
in vitro inhibition of hypertrophy 
FIgURE 2. MicroRNAs in health and disease. MicroRNAs are implicated in cardiac physiology and pathology. These roles render 
them valuable biomarkers for diagnostic and prognostic purposes, as well as promising therapeutic targets. DCM = dilated cardio-
myopathy; HF = heart failure.
have been implicated in heart disease onset and progression, 
whereas in the case of cardiac hypertrophy and heart failure, 
recent data are changing our perception of disease pathogen-
esis and therapeutics.
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alone does not seem to lead to a pathological phenotype in 
vivo. An explanation for this finding may be provided by an-
other study, reporting that only the combined overexpression 
of miRNAs (specifically miR-21, miR-129 and miR-212), as 
opposed to their separate overexpression, could lead to hyper-
trophy.13 These findings accentuate miRNAs’ critical role in 
cardiac function, the differences between them but also their 
synergistic action.
Further elucidating the role of miR-23a in cardiac hyper-
trophy, it was shown that its expression was directly activated 
by the nuclear factor of activated T cells 3 (NFATc3), and in 
turn it targeted and suppressed the negative regulator muscle 
ring finger1 (MuRF1). Treatment with anti-miRNA oligo-
nucleotides (antagomirs – described in section “MicroRNAs 
as therapeutic targets”) led to MuRF1 upregulation and 
inhibition of isoproterenol-induced cardiac hypertrophy in 
mouse hearts.15 Of note, mice with MuRF1 ablation present 
with pressure-induced hypertrophy.15,16 These findings together 
support that miR-23a acts as a mediator of the calcineurin/
NFATc3 pathway, facilitating its prohypertrophic action, which 
is consistent with observations of miR-23a upregulation in 
pressure overload- induced14,17-19 and isoproterenol-induced 
cardiac hypertrophy.15 
The calcineurin/NFAT pathway seems to play a pivotal 
role in hypertrophy regulation by miRNAs, with more than 
miR-23a being implicated in the process. MiR-199b upregu-
lation, recorded in patients and mouse models with heart 
failure, acts through the calcineurin/NFAT in hypertrophy as 
well. In addition, NFAT activates miR-199b expression, thus 
allowing miR-199b to suppress NFAT’s negative regulator 
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 
1a (Dyrk1a), participating in an auto-amplification loop. In 
accordance, severe pressure-overload induced cardiac hyper-
trophy develops via Dyrk1a downregulation in transgenic mice 
overexpressing miR-199b or being Dyrk1a haploinsufficient. 
Consistently, when miR199b levels were normalized by an-
tagomirs, hypertrophy and heart failurre were inhibited and 
the phenotype was reversed.20 MiR-23a and miR199b serve as 
mediators of the calcineurin/NFAT pathway in hypertrophy 
and could have a therapeutic potential. Meantime, a possible 
synergistic action of these two miRs towards hypertrophy 
remains to be investigated. 
Another miRNA likely implicated in the pathogenesis of 
cardiac hypertrophy and heart failure is miR-27b. In mouse 
models of cardiac hypertrophy induced by cardiac-specific 
Smad4 ablation, miR-27b upregulated, while its cardiac-
specific overexpression in transgenic mice suffices to induce 
hypertrophy and dysfunction, and its suppression could inhibit 
phenylephrine-induced hypertrophy in vitro.21 Ttransform-
ing growth factor-1 (TGF-1) was shown to inhibit miR-27b 
expression and peroxisome proliferator-activated receptor γ 
(PPARγ) was verified as a direct target. These findings were 
further confirmed in a pressure overload-induced heart failure 
mouse model treated with 27b antagomirs.21
MiR-208, being exclusively expressed in the heart, is an-
other promising miRNA implicated in hypertrophy. Although 
it does not affect cardiac development, its absence inhibits the 
development of hypertrophy. Specifically, miR-208 ablation in 
genetically modified mice is not associated with any develop-
mental abnormality or pathological heart condition during the 
first months of life. Only a slight decrease in cardiac function 
is noted after the first two months, which seemed to deterio-
rate with age. Strikingly however, these mice do not develop 
hypertrophy upon exposure to pro-hypertrophic stimuli includ-
ing activation of calcineurin pathway, pressure overload or 
hypothyroidism.22 Since miR-208 loss leads to elevated thyroid 
hormone receptor-associated protein 1 (Thrap1) levels, it is 
possible for miR-208 to act via Thrap1. These findings estab-
lish a connection between miRNAs and hormone-regulated 
cardiac muscle physiology, and could further improve our 
understanding of cardiac function and its regulation.
Complementary studies demonstrated that miR-208 func-
tions together with miR499 to regulate the “myosin switch”, 
part of the fetal gene program activated during hypertrophy. 
MiR-208 has two isoforms, miR208a and miR-208b, both of 
which are sources of mature miR-208. MiR-208a, located in 
the Myh 6 (αΜyh) intronic region, regulates the expression 
of βMyh myosin genes Myh7 and Myh7b, and their respective 
intronic miRNAs: miR-208b and miR-499, in the adult heart.23 
Developmentally normal neonatal transgenic mice lacking 
miR-208a had the expected levels of αΜyh and βMyh, whilst 
adult transgenic mice exhibited decreased miR499 levels, did 
not present with the expected βMyh upregulation and did not 
develop hypertrophy in response to hypothyroidism.22 Consist-
ently, overexpression of miR499 in miR-208a deficient mice 
restored the βMyh levels and the normal hypertrophic response 
to thyroid hormone inhibition, indicating that miR499 acts 
downstream of miR-208a.23 Meanwhile, overexpression of 
miR-208a in transgenic mice induced hypertrophic growth 
likely through Thrap1 and myostatin suppression, without 
however, upregulation of atrial natriuretic factor or βMyh, 
or significant alterations in hypertrophy-related miRNAs’ 
expression levels. Moreover, the transgenic mice presented 
with arrhythmias, indicating that miR-208a is essential for 
normal cardiac conduction, as well.24 
A pro-hypertrophic role has also been attributed to mir-
199a. Specifically, its knockdown resulted in cell size decrease 
and attenuation of phenylephrine-induced hypertrophy, 
whereas its overexpression in vitro led to increased cell size 
and decreased αΜyh.25 
A N T I - H y P E R T R O P H I C  M i R N A s
Apart from overexpression, downregulation of specific 
miRNAs can also contribute to cardiac hypertrophy indicating 
an antihyperyrophic role. For example, miR-1 and miR-133 
downregulation suffices to trigger cardiac hypertrophy in 
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overall healthy animals, whereas their overexpression in in vitro 
hypertrophy models inhibits the hypertrophic phenotype.17,26 
This is likely achieved through modulation of multiple mo-
lecular mechanisms. One study demonstrated that these two 
miRNAs are involved in cardiomyocyte apoptosis, via heat 
shock protein 60 (HSP60), HSP70 and caspase 9,27 and another 
implicated miR-1 in calmodulin downregulation and NFAT/
calcineurin mediated reduction of calcium-calmodulin signal-
ing.28 Furthermore the calcium dependent transcription fac-
tors MEF2A and GATA4 were downregulation. Since NFAT 
and MEF2A cooperate with the transcription factor GATA4 
to activate hypertrophic gene expression in cardiomyocytes, 
miR-1 exerts its antihypertrophic role, at least in part, through 
regulation of an essential subset of cardiac genes.29 
M I C R O R N A s ’  P O T E N T I A L  
I N  T H E  D I A g N O S T I C  
A N D  P R O g N O S T I C  S E T T I N g
Although deciphering disease pathogenesis is the first 
step towards combating it, the identification of diagnostic 
and prognostic markers remains another crucial aspect in 
improving quality of life, healthcare and treatment selection. 
MicroRNAs are promising to make a significant contribution 
towards this direction as well. Although miRNA expression 
in cardiac tissue has been studied in the research setting, a 
number of steps are still needed in terms of validation of the 
research findings to the clinical setting, as well as develop-
ment of suitable (accurate, easy and economical) molecular 
tests. Towards this direction, circulating miRNAs could 
serve a valuable role in the cardiology clinic. For example, in 
a rat model of isoproterenol-induced myocardial injury the 
levels of circulating miR-208 were significantly (P <0.0001) 
increased, along with cardiac troponin I (cTnI), which is a 
widely used biomarker of myocardial injury.30 Similarly, in 
humans, upregulation of miR-1,31,32 miR-208a,33 miR-208b,34 
miR-133, miR328,35 and miR-499,34,36 has been reported in 
acute myocardial infarction patients in comparison with con-
trols, while increased levels of the circulating miR-423-5p and 
miR-499 have been associated with heart failure. In parallel 
to upregulation, miRNA downregulation can also serve as a 
disease marker as exemplified by the coronary artery disease 
related underexpression of miR-126, miR-17 and miR-92a.37 
M I C R O R N A s  A S  T H E R A P E U T I C  T A R g E T S
The emerging critical role of miRNAs in cardiac function 
and disease pathogenesis renders them promising therapeutic 
targets. The inactivation of miRNA targets could be achieved 
either by directly targeting selected miRNA molecules or by 
inhibiting miRNA binding to their mRNA targets. A variety 
of molecular tools are already available to enable the targeted 
modulation of miRNA pathways. The two main categories 
include 1) anti-miRNAs (antagomirs), modified antisense 
oligonucleotides that bind selected mature microRNAs and 
reduce their intracellular levels; 2) miRNA mimics, that mimic 
the action of selected miRNAs.38 
Specifically, anti-miRNAs (antagomirs) can act at multiple 
levels including i) binding to mature miRNA within the RNA-
induced silencing complex (RISC) and serving as a competitive 
inhibitor, ii) binding to pre-miRNA and inhibiting their pro-
cessing and incorporation to the RISC complex, and iii) inhib-
iting the processing or the exit of pre-miRNA or pri-miRNA 
from the nucleus. In all cases the end result is the increase in 
the levels of the selected mRNA. For example, administration 
of antimiR-21 to a mouse pressure-overload-induced disease 
model inhibited interstitial fibrosis and attenuated cardiac 
dysfunction.39 Similarly, treatment of Dahl hypertensive rats 
with hypertension-induced heart failure, with antimiR-208a 
resulted in prevention of pathological “myosin switching” and 
cardiac remodeling, whereas cardiac function, overall health 
and survival were markedly improved.40
On the other hand, miRNA mimics aim at decreasing the 
levels of selected mRNAs. For example, miR-9, a suppressor 
of myocardin, is downregulated in cardiac hypertrophy and 
has been considered a potential therapeutic target. A double-
stranded RNA miRNA mimic for miR-9 was recently assessed 
in vivo, in an isoproterenol-induced cardiac hypertrophy rat 
model, and successfully reduced myocardin levels, leading 
to attenuation of cardiac hypertrophy and improvement of 
cardiac function.41 
Other emerging miRNA-related therapeutic approaches 
include the miRNA sponges, the miRNA erasers and the 
locked-nucleic acid (LNA) chemistry, which was only recently 
successfully employed in primates.42
Although miRNA modulation stands as a highly promis-
ing tool in the therapeutic setting, significant efforts are still 
required in order to understand their full spectrum of func-
tions, their exact pharmacodynamic and pharmacokinetic 
characteristics, as well as their potential adverse reactions or 
side effects. Moreover, direct comparisons of the specificity 
and efficacy of the different miRNA antagonism and mimick-
ing chemistries will need to be made and the most effective 
route and means of administration need to be determined.
F U T U R E  D I R E C T I O N S  /  P E R S P E C T I V E S
The developments in the miRNA field are rapid, with 
thousands of publications in PubMed over the course of a 
decade. The emerging findings are not only promoting our 
understanding of different biological systems, such as the 
pathogenetic mechanisms of cardiovascular disease, but im-
portantly, they are promising to soon transition to the Clinic. 
14
HOSPITAL CHRONICLES 7(1), 2012
It is anticipated that in the near future monitoring of miRNA 
expression will serve as routine diagnostic and/or prognostic 
testing. Large scale, multi-ethnic studies will first need to 
validate the accuracy of different miRNA markers and the 
sensitivity of different analytical approaches. Specific and 
detailed guidelines will then need to be established by inter-
national regulatory authorities and accreditation mechanisms 
will have to be set in place for miRNA diagnostic laboratories. 
Once this framework is available, miRNA diagnostic testing 
could be performed using either a biopsy of the affected organ / 
tissue or withdrawal of body fluids (e.g. plasma, saliva, semen). 
The cutting-edge technologies such as microarrays and next-
generation sequencing are transforming the field through ultra 
rapid analysis of the miRNome, while for targeted evaluation 
of specific miRNA-markers, more classical molecular biology 
approaches can be applied. Interpretation of the results will 
require the continuous education of clinicians and their close 
collaboration of biomedical scientists. The test results would 
ultimately ensure more accurate, potentially faster diagnosis/
prognosis, and are anticipated to contribute towards the se-
lection of targeted, and therefore, more effective therapies.
C O N C L U S I O N
Despite our only recent encounter with miRNAs, extensive 
research has revealed their significant role in a broad range of 
physiological and pathological mechanisms. In the context of 
heart failure, miRNAs have been directly implicated in its on-
set and progression, while the latest findings are now changing 
our perception of disease pathogenesis. Importantly, miRNAs 
have opened the way to a new line of therapeutic approaches 
that could play a significant role in the near future.
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